TP53 and Ewing sarcoma: This study establishes a novel anti-cancer strategy to treat ES cells by combination of low-dosed HSP90i and ATRi, which proved to be highly effective irrespective of the p53 status, thus offering the possibility to target even therapy-resistant or metastatic ES.